Gencurix Inc Asset Resilience Ratio

Latest as of June 2025: 4.01%

Gencurix Inc asset resilience ratio. Gencurix Inc (229000) has an Asset Resilience Ratio of 4.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gencurix Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩1.08 Billion
≈ $730.31K USD Cash + Short-term Investments

Total Assets

₩26.90 Billion
≈ $18.23 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Gencurix Inc (2016–2024)

Asset resilience ratio of Gencurix Inc from 2016 to 2024. This chart shows how Gencurix Inc's Asset Resilience Ratio has changed over time. Read debt load of Gencurix Inc for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Gencurix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Gencurix Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩1.08 Billion 4.01%
Total Liquid Assets ₩1.08 Billion 4.01%

Asset Resilience Insights

  • Limited Liquidity: Gencurix Inc maintains only 4.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Gencurix Inc Industry Peers by Asset Resilience Ratio

Compare Gencurix Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Voxel S.A.
WAR:VOX
Diagnostics & Research 0.32%
Leveljump Healthcare Corp
V:JUMP
Diagnostics & Research 32.45%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Gencurix Inc Asset Resilience Ratio by Year (2016–2024)

Gencurix Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Gencurix Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 15.11% ₩4.54 Billion
≈ $3.08 Million
₩30.04 Billion
≈ $20.36 Million
-18.54pp
2023-12-31 33.65% ₩11.27 Billion
≈ $7.64 Million
₩33.50 Billion
≈ $22.70 Million
+17.65pp
2022-12-31 16.01% ₩5.96 Billion
≈ $4.04 Million
₩37.24 Billion
≈ $25.24 Million
-23.72pp
2021-12-31 39.73% ₩21.96 Billion
≈ $14.88 Million
₩55.29 Billion
≈ $37.47 Million
+30.93pp
2020-12-31 8.80% ₩5.63 Billion
≈ $3.81 Million
₩63.98 Billion
≈ $43.36 Million
-16.06pp
2019-12-31 24.85% ₩593.34 Million
≈ $402.10K
₩2.39 Billion
≈ $1.62 Million
-46.40pp
2018-12-31 71.25% ₩7.23 Billion
≈ $4.90 Million
₩10.14 Billion
≈ $6.87 Million
+9.81pp
2017-12-31 61.44% ₩4.52 Billion
≈ $3.07 Million
₩7.36 Billion
≈ $4.99 Million
-7.41pp
2016-12-31 68.85% ₩6.36 Billion
≈ $4.31 Million
₩9.23 Billion
≈ $6.26 Million
--
pp = percentage points

About Gencurix Inc

KQ:229000 Korea Diagnostics & Research
Market Cap
$31.07 Million
₩45.85 Billion KRW
Market Cap Rank
#23452 Global
#1610 in Korea
Share Price
₩1957.00
Change (1 day)
+0.88%
52-Week Range
₩1400.00 - ₩5870.00
All Time High
₩23845.65
About

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more